FRESENIUS MEDICAL CARE AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.42 EUR | -0.98% |
|
+2.18% | -1.42% |
| 26/04 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Gets a Sell rating from Jefferies | ZD |
| 24/04 | European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.42% | 11.72B | A- | ||
| -14.92% | 84.68B | B- | ||
| +13.30% | 81.12B | C+ | ||
| +11.62% | 29.4B | C+ | ||
| -12.71% | 16.73B | B | ||
| -3.06% | 16.36B | A- | ||
| -2.63% | 14.92B | A- | ||
| -31.75% | 11.77B | - | - | |
| +27.44% | 11.71B | B- | ||
| -3.97% | 11.66B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- FME Stock
- Ratings Fresenius Medical Care AG
